Laura Mitic, PhD

Title(s)Specialist, Neurology
SchoolSchool of Medicine
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San Francisco, San FranciscoPostdoctoral Studies2008Genetics of Aging
    Yale University, New HavenPostdoctoral Studies2002Structural Biology
    Yale University, New HavenPhD2000Cell Biology
    Northwestern University, EvanstonBA1995Molecular Cell Biology

    Collapse Overview 
    Collapse Overview
    As the Chief Scientific Officer for the Bluefield Project to Cure Frontotemporal Dementia, I work to enable and accelerate basic, clinical and translational research in frontotemporal dementia (FTD) caused by mutations in the lysosomal protein progranulin (GRN). With our aggressive timeline to find a cure or therapy for GRN-FTD, I foster highly focused, rapid and collaborative discovery research and engage with industry partners to advance drug development for this devastating disease.

    Collapse ORNG Applications 
    Collapse Websites
    Collapse Twitter

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Sha SJ, Miller ZA, Min SW, Zhou Y, Brown J, Mitic LL, Karydas A, Koestler M, Tsai R, Corbetta-Rastelli C, Lin S, Hare E, Fields S, Fleischmann KE, Powers R, Fitch R, Martens LH, Shamloo M, Fagan AM, Farese RV, Pearlman R, Seeley W, Miller BL, Gan L, Boxer AL. An 8-week, open-label, dose-finding study of nimodipine for the treatment of progranulin insufficiency from GRN gene mutations. Alzheimers Dement (N Y). 2017 Nov; 3(4):507-512. PMID: 29124108.
      View in: PubMed
    2. Nicholson AM, Finch NA, Almeida M, Perkerson RB, van Blitterswijk M, Wojtas A, Cenik B, Rotondo S, Inskeep V, Almasy L, Dyer T, Peralta J, Jun G, Wood AR, Frayling TM, Fuchsberger C, Fowler S, Teslovich TM, Manning AK, Kumar S, Curran J, Lehman D, Abecasis G, Duggirala R, Pottier C, Zahir HA, Crook JE, Karydas A, Mitic L, Sun Y, Dickson DW, Bu G, Herz J, Yu G, Miller BL, Ferguson S, Petersen RC, Graff-Radford N, Blangero J, Rademakers R. Prosaposin is a regulator of progranulin levels and oligomerization. Nat Commun. 2016 06 30; 7:11992. PMID: 27356620.
      View in: PubMed
    3. Bettcher BM, Fitch R, Wynn MJ, Lalli MA, Elofson J, Jastrzab L, Mitic L, Miller ZA, Rabinovici GD, Miller BL, Kao AW, Kosik KS, Kramer JH. MCP-1 and eotaxin-1 selectively and negatively associate with memory in MCI and Alzheimer's disease dementia phenotypes. Alzheimers Dement (Amst). 2016; 3:91-7. PMID: 27453930.
      View in: PubMed
    4. Nguyen AD, Nguyen TA, Martens LH, Mitic LL, Farese RV. Progranulin: at the interface of neurodegenerative and metabolic diseases. Trends Endocrinol Metab. 2013 Dec; 24(12):597-606. PMID: 24035620.
      View in: PubMed
    5. Boxer AL, Gold M, Huey E, Hu WT, Rosen H, Kramer J, Gao FB, Burton EA, Chow T, Kao A, Leavitt BR, Lamb B, Grether M, Knopman D, Cairns NJ, Mackenzie IR, Mitic L, Roberson ED, Van Kammen D, Cantillon M, Zahs K, Jackson G, Salloway S, Morris J, Tong G, Feldman H, Fillit H, Dickinson S, Khachaturian ZS, Sutherland M, Abushakra S, Lewcock J, Farese R, Kenet RO, Laferla F, Perrin S, Whitaker S, Honig L, Mesulam MM, Boeve B, Grossman M, Miller BL, Cummings JL. The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier). Alzheimers Dement. 2013 Mar; 9(2):189-98. PMID: 23062850.
      View in: PubMed
    6. Boxer AL, Gold M, Huey E, Gao FB, Burton EA, Chow T, Kao A, Leavitt BR, Lamb B, Grether M, Knopman D, Cairns NJ, Mackenzie IR, Mitic L, Roberson ED, Van Kammen D, Cantillon M, Zahs K, Salloway S, Morris J, Tong G, Feldman H, Fillit H, Dickinson S, Khachaturian Z, Sutherland M, Farese R, Miller BL, Cummings J. Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development. Alzheimers Dement. 2013 Mar; 9(2):176-88. PMID: 23043900; PMCID: PMC3542408.
    7. Van Itallie CM, Mitic LL, Anderson JM. SUMOylation of claudin-2. Ann N Y Acad Sci. 2012 Jul; 1258:60-4. PMID: 22731716.
      View in: PubMed
    8. Van Itallie CM, Mitic LL, Anderson JM. Claudin-2 forms homodimers and is a component of a high molecular weight protein complex. J Biol Chem. 2011 Feb 04; 286(5):3442-50. PMID: 21098027; PMCID: PMC3030350.
    9. Hansen M, Chandra A, Mitic LL, Onken B, Driscoll M, Kenyon C. A role for autophagy in the extension of lifespan by dietary restriction in C. elegans. PLoS Genet. 2008 Feb; 4(2):e24. PMID: 18282106; PMCID: PMC2242811.
    10. Mitic LL, Unger VM, Anderson JM. Expression, solubilization, and biochemical characterization of the tight junction transmembrane protein claudin-4. Protein Sci. 2003 Feb; 12(2):218-27. PMID: 12538885; PMCID: PMC2312412.
    11. Singh U, Mitic LL, Wieckowski EU, Anderson JM, McClane BA. Comparative biochemical and immunocytochemical studies reveal differences in the effects of Clostridium perfringens enterotoxin on polarized CaCo-2 cells versus Vero cells. J Biol Chem. 2001 Sep 07; 276(36):33402-12. PMID: 11445574.
      View in: PubMed
    12. Rahner C, Mitic LL, Anderson JM. Heterogeneity in expression and subcellular localization of claudins 2, 3, 4, and 5 in the rat liver, pancreas, and gut. Gastroenterology. 2001 Feb; 120(2):411-22. PMID: 11159882.
      View in: PubMed
    13. Medina R, Rahner C, Mitic LL, Anderson JM, Van Itallie CM. Occludin localization at the tight junction requires the second extracellular loop. J Membr Biol. 2000 Dec 01; 178(3):235-47. PMID: 11140279.
      View in: PubMed
    14. Mitic LL, Van Itallie CM, Anderson JM. Molecular physiology and pathophysiology of tight junctions I. Tight junction structure and function: lessons from mutant animals and proteins. Am J Physiol Gastrointest Liver Physiol. 2000 Aug; 279(2):G250-4. PMID: 10915631.
      View in: PubMed
    15. Singh U, Van Itallie CM, Mitic LL, Anderson JM, McClane BA. CaCo-2 cells treated with Clostridium perfringens enterotoxin form multiple large complex species, one of which contains the tight junction protein occludin. J Biol Chem. 2000 Jun 16; 275(24):18407-17. PMID: 10749869.
      View in: PubMed
    16. Mitic LL, Schneeberger EE, Fanning AS, Anderson JM. Connexin-occludin chimeras containing the ZO-binding domain of occludin localize at MDCK tight junctions and NRK cell contacts. J Cell Biol. 1999 Aug 09; 146(3):683-93. PMID: 10444075; PMCID: PMC2150551.
    17. Fanning AS, Mitic LL, Anderson JM. Transmembrane proteins in the tight junction barrier. J Am Soc Nephrol. 1999 Jun; 10(6):1337-45. PMID: 10361874.
      View in: PubMed
    18. Mitic LL, Anderson JM. Molecular architecture of tight junctions. Annu Rev Physiol. 1998; 60:121-42. PMID: 9558457.
      View in: PubMed